Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm

1 Jan 2006

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Biosensing Techniques and Applications
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 16444193
DOI: 10.1038/modpathol.3800555

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithmPMID 16444193Read ↗

Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assesment in breast cancerSemantic proximity Read ↗

Chromogenic In Situ Hybridization: A Novel Approach to a Practical and Sensitive Method for the Detection of HER2 Oncogene in Archival Human Breast CarcinomaSemantic proximity Read ↗

Detection of ERBB2 and CEN17 signals in fluorescent in situ hybridization and dual in situ hybridization for guiding breast cancer HER2 target therapySemantic proximity Read ↗

Chromogenic In Situ HybridizationSemantic proximity Read ↗

Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancersSemantic proximity Read ↗

HER2 Positivity in Breast Carcinoma: A Comparison of Chromogenic In Situ Hybridization With Fluorescence In Situ Hybridization in Tissue Microarrays, With Targeted Evaluation of Intratumoral Heterogeneity by In Situ HybridizationSemantic proximity Read ↗

Emerging Technologies for Assessing HER2 AmplificationSemantic proximity Read ↗

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerSemantic proximity Read ↗

Automated brightfield break-apart in situ hybridization (ba-ISH) application: ALK and MALT1 genes as modelsSemantic proximity Read ↗

Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplificationSemantic proximity Read ↗

Chromogenic <i>in situ</i> hybridization for Her‐2/neu‐oncogene in breast cancer: comparison of a new dual‐colour chromogenic <i>in situ</i> hybridization with immunohistochemistry and fluorescence <i>in situ</i> hybridizationSemantic proximity Read ↗

Determination of <i>HER2</i> amplification in primary breast cancer using dual‐colour chromogenic <i>in situ</i> hybridization is comparable to fluorescence <i>in situ</i> hybridization: a European multicentre study involving 168 specimensSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.